Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Samsung Bioepis Receives First FDA Drug Approval for Remicade Biosimilar

XTALKS VITALS NEWS

The company’s biosimilar of Johnson & Johnson’s Remicade (infliximab) was approved for all eligible indications.

Share this!

April 26, 2017 | by Sarah Hand, M.Sc.

South Korea-based biopharmaceutical company, Samsung Bioepis, has received its first product approval for the US market. The company’s biosimilar of Johnson & Johnson’s Remicade (infliximab) was approved for all eligible indications.

Samsung Bioepis’ Renflexis (infliximab-abda) has been approved by the FDA to treat rheumatoid arthritis and Chrohn’s disease, along with other autoimmune diseases. The drug is the second biosimilar version of Remicade to be approved by the regulator, potentially threatening Johnson & Johnson’s $7 billion in annual sales for the biologic.

“Since our company was established five years ago, we have strived day in and day out to realize the promise of biosimilars for patients across the United States by offering them treatment options at a lower cost. We hope this regulatory milestone will bring us a step closer to achieving this goal,” said Christopher Hansung Ko, President & CEO of Samsung Bioepis. “Through relentless process innovation and an uncompromising commitment to quality, we remain committed to advancing one of the industry's strongest biosimilar pipelines.”

Remicade can cost over $30,000 per year for an adult patient without insurance coverage. While it’s unclear exactly how Renflexis will be priced, it’s likely that it will be less expensive compared to the reference biologic.



Renflexis is an injectable biologic which blocks the action of a cell signaling protein known as tumor necrosis factor (TNF). The biosimilar does contain the same FDA-mandated boxed warning as its reference biologic, which warns doctors and patients of an increased risk of serious infections, such as tuberculosis, which could be fatal.

Renflexis has already been approved in 28 EU member states under the trade name Flixabi, along with a few countries in the Asia-Pacific. The biosimilar will be marketed and distributed in the US by Samsung’s partner, Merck.

Last year, Pfizer and Celltrion’s Inflectra became the first biosimilar of Remicade to be approved in the US. Samsung Bioepis expects that Renflexis will be available in the US in the next six months.


Keywords:  FDA, Biosimilar, Arthritis


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.